Atemwegsinfektionen in đ©đȘ - zur aktuellen Situation
âŸïž hohe AktivitĂ€t fĂŒr die Jahreszeit (Ă€hnlich wie letzten Winter)
âŸïž bei schweren FĂ€llen und Erwachsenen dominiert seit Wochen Covid-19 als Ursache
âŸïž saisonale Covid-Welle scheint von pandemischer JN.1-Welle abgelöst zu werden
Dieser Artikel ist so gut, ich möchte ihn Menschen auf die Netzhaut kleben. Danke. #CovidIsNotOver #teamvorsicht
(Leute, auch wenn ihr den Artikel so gut findet wie ich, war das keine Einladung, mir sĂ€mtliche dystopische Zukunftsszenarien drunter zu kippen. Ich weiĂ das alles, aber mir meine KĂ€mpfe auszusuchen, ist mein gutes Recht, also please donât.)
Macht #COVID19 das Immunsystem kaputt?
Epidemiologin Kately Jetelina und Mikrobiologe Edward Nirenberg @enirenberg fassen in einem kurzen Artikel zusammen, warum es fĂŒr die BefĂŒrchtung, dass #SARSCoV2 das Immunsystem ĂŒber lĂ€ngere Zeit in einem signifikanten AusmaĂ schĂ€digen wĂŒrde, weder epidemiologisch noch immunologisch wirkliche Evidenz gibt (auĂer nach schwerer Erkrankung).
#COVID19 ist und bleibt eine potentiell sehr gefÀhrliche Krankheit mit heftigen Langzeitfolgen - und eine reduzierte Immunabwehr kann ein Symptom von #LongCovid sein. Aber es ist wohl kein "airborne Aids".
https://yourlocalepidemiologist.substack.com/p/has-covid-messed-with-our-immune
Objective To investigate the effectiveness of primary covid-19 vaccination (first two doses and first booster dose within the recommended schedule) against post-covid-19 condition (PCC). Design Population based cohort study. Setting Swedish Covid-19 Investigation for Future Insightsâa Population Epidemiology Approach using Register Linkage (SCIFI-PEARL) project, a register based cohort study in Sweden. Participants All adults (â„18 years) with covid-19 first registered between 27 December 2020 and 9 February 2022 (n=589â722) in the two largest regions of Sweden. Individuals were followed from a first infection until death, emigration, vaccination, reinfection, a PCC diagnosis (ICD-10 diagnosis code U09.9), or end of follow-up (30 November 2022), whichever came first. Individuals who had received at least one dose of a covid-19 vaccine before infection were considered vaccinated. Main outcome measure The primary outcome was a clinical diagnosis of PCC. Vaccine effectiveness against PCC was estimated using Cox regressions adjusted for age, sex, comorbidities (diabetes and cardiovascular, respiratory, and psychiatric disease), number of healthcare contacts during 2019, socioeconomic factors, and dominant virus variant at time of infection. Results Of 299â692 vaccinated individuals with covid-19, 1201 (0.4%) had a diagnosis of PCC during follow-up, compared with 4118 (1.4%) of 290â030 unvaccinated individuals. Covid-19 vaccination with any number of doses before infection was associated with a reduced risk of PCC (adjusted hazard ratio 0.42, 95% confidence interval 0.38 to 0.46), with a vaccine effectiveness of 58%. Of the vaccinated individuals, 21â111 received one dose only, 205â650 received two doses, and 72â931 received three or more doses. Vaccine effectiveness against PCC for one dose, two doses, and three or more doses was 21%, 59%, and 73%, respectively. Conclusions The results of this study suggest a strong association between covid-19 vaccination before infection and reduced risk of receiving a diagnosis of PCC. The findings highlight the importance of primary vaccination against covid-19 to reduce the population burden of PCC.
Laborarzt
Wusel 
Wolfgang Hagen
Volksverpetzer
